The Use of Adeno-associated virus (AAV) in Vaccine Development


 Adeno-associated virus (AAV) is a very tiny (20-26 nm) icosahedral and non-enveloped virus, it belongs to the Parvoviridae family. AAV vectors are most widely used option for gene therapy delivery of therapeutic antibodies due their relatively low immunogenicity, high safety profile, broad tropism, tendency maintain long-term expression [1]. AVV developed by transfection human embryonic kidney (HEK) 293 T cells with transgene, packaging helper plasmids [2]. Several clinical studies have investigated use in treating Parkinson’s disease, Alzheimer’s heart prostate cancer [3]. previously been treat muscular diseases, but recent years, usage as vaccine cure or prevent infectious diseases including HIV, HPV, influenza has expanded [4].
 Here, we discuss advantages disadvantages development, future approaches improving drawbacks caused AAV-based vaccines. Numerous animal investigations conducted explore against various illnesses, suggesting possibility vaccinations. Clinical on humans are, however, uncommon because, contrast other viral vectors, induces poor humoral cellular immune response. Additionally, vaccinations often target large group healthy individuals across variety ages, children teenagers. Therefore, compared therapies, based need be more cost-effective robust control.
 According several research, vector vaccines shown induce stronger longer lasting antibody response comparison vaccination approaches, such DNA, recombinant proteins, inactivated viruses, virus-like particles (VLPs) [5]. However, thought immunogenic profile vectors. The main limitations transgenic capacity widespread pre-existing immunity [6]. Currently, strategies immunogenicity circumventing actively being investigated. research undertaken so far highlighted numerous significant benefits immunisation. Despite all advantages, there still challenges that limit these humans. Thus, necessary overcome order make effective.